Ibaraki, Japan

Yoichi Miyamoto

This inventor holds 2 USPTO granted patents. Top assignees: Hiroshi Maeda, Other. Active years: 1995-1998.


% Patents Active = 100.0

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1995-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yoichi Miyamoto: Innovator in Antihypertensive Agents

Introduction

Yoichi Miyamoto is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antihypertensive agents. With a total of 2 patents, his work has the potential to impact the treatment of hypertension.

Latest Patents

Miyamoto's latest patents include a method for treating hypertension using pyrazolopyrimidine derivatives. This innovative approach involves antihypertensive agents containing as its active ingredient the 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine (AHPP) or its derivatives. The general formula for these compounds includes variations where R can be a hydrogen atom, alkyl group, or aryl group. Additionally, he has worked on 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide derivatives.

Career Highlights

Throughout his career, Yoichi Miyamoto has focused on advancing medical treatments through innovative research. His dedication to developing effective antihypertensive agents showcases his commitment to improving patient outcomes.

Collaborations

Miyamoto has collaborated with notable individuals in his field, including Hiroshi Maeda and Takaaki Akaike. These partnerships have likely contributed to the success of his research and patent applications.

Conclusion

In summary, Yoichi Miyamoto is a distinguished inventor whose work in antihypertensive agents has the potential to make a significant impact in the medical field. His innovative approaches and collaborations highlight his contributions to pharmaceutical advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…